Introduction
Materials and methods
Patients
Detection of RF and ACPAs
HLA-DRB1 genotyping and allele classification
HLA-DRB1 allele | Amino acid position | Classification of du Montcel and colleagues | |||||||
---|---|---|---|---|---|---|---|---|---|
69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | ||
HLA-DRB1*0101 | E |
Q
|
R
|
R
|
A
|
A
| V | D |
S3P
|
HLA-DRB1*0102 | - |
Q
|
R
|
R
|
A
|
A
| - | - |
S3P
|
HLA-DRB1*0103 | - | D |
E
|
R
|
A
|
A
| - | - |
S1
|
HLA-DRB1*03 | - | - | K | - | G | R | - | - |
X
|
HLA-DRB1*0401 | - | Q |
K
|
R
|
A
|
A
| - | - |
S2
|
HLA-DRB1*0402 | - | D |
E
|
R
|
A
|
A
| - | - |
S1
|
HLA-DRB1*0403 | - | - | - | - | - | E | - | - |
X
|
HLA-DRB1*0404 | - |
Q
|
R
|
R
|
A
|
A
| - | - |
S3P
|
HLA-DRB1*0405 | - |
Q
|
R
|
R
|
A
|
A
| - | - |
S3P
|
HLA-DRB1*0407 | - | - | - | - | - |
E
| - | - |
X
|
HLA-DRB1*0408 | - |
Q
|
R
|
R
|
A
|
A
| - | - |
S3P
|
HLA-DRB1*0411 | - | - | - | - | - | E | - | - |
X
|
HLA-DRB1*07 | - | D | - | - | G | Q | - | - |
X
|
HLA-DRB1*08 | - | D | - | - | - | L | - | - |
X
|
HLA-DRB1*0901 | - | R | - | - | - | E | - | - |
X
|
HLA-DRB1*1001 | - |
Q
|
R
|
R
|
A
|
A
| - | - |
S3P
|
HLA-DRB1*1101 | - |
D
|
R
|
R
|
A
|
A
| - | - |
S3D
|
HLA-DRB1*1102 | - | D |
E
|
R
|
A
|
A
| - | - |
S1
|
HLA-DRB1*1103 | - | D |
E
|
R
|
A
|
A
| - | - |
S1
|
HLA-DRB1*1104 | - |
D
|
R
|
R
|
A
|
A
| - | - |
S3D
|
HLA-DRB1*12 | - |
D
|
R
|
R
|
A
|
A
| - | - |
S3D
|
HLA-DRB1*1301 | - | D |
E
|
R
|
A
|
A
| - | - |
S1
|
HLA-DRB1*1302 | - | D |
E
|
R
|
A
|
A
| - | - |
S1
|
HLA-DRB1*1303 | - | D |
K
|
R
|
A
|
A
| - | - |
S2
|
HLA-DRB1*1323 | - | D |
E
|
R
|
A
|
A
| - | - |
S1
|
HLA-DRB1*1401 | - | R | - | - | - | E | - | - |
X
|
HLA-DRB1*1402 | - |
Q
|
R
|
R
|
A
|
A
| - | - |
S3P
|
HLA-DRB1*1404 | - | R | - | - | - | E | - | - |
X
|
HLA-DRB1*15 | - | Q |
A
|
R
|
A
|
A
| - | - |
S1
|
HLA-DRB1*16 | - |
D
|
R
|
R
|
A
|
A
| - | - |
S3D
|
Statistical analysis
Results
Demographic and immunologic characteristics of RA patients
Allele frequencies for HLA-DRB1 polymorphisms
Relationship between HLA-DRB1 allele carrier status and RF status
Carrier status | Odds ratio (95% confidence interval) |
P
| P for trend | ||
---|---|---|---|---|---|
Yes | No | ||||
S1 carrier | |||||
Rheumatoid factor-positive | 31 (55.4) | 79 (75.9) | 0.39 (0.19–0.83) | 0.0118 | 0.0051* |
Rheumatoid factor-negative | 25 (44.6) | 25 (24.0) | |||
S2 carrier | |||||
Rheumatoid factor-positive | 49 (83.1) | 61 (60.4) | 3.21 (1.39–7.9) | 0.0028* | 0.0049* |
Rheumatoid factor-negative | 10 (16.9) | 40 (39.6) | |||
S3P carrier | |||||
Rheumatoid factor-positive | 57 (74.0) | 53 (63.9) | 1.61 (0.78–3.38) | 0.1766 | 0.4478 |
Rheumatoid factor-negative | 20 (26.0) | 30 (36.1) | |||
S3D carrier | |||||
Rheumatoid factor-positive | 19 (51.4) | 91 (74.0) | 0.37 (0.16–0.86) | 0.0145 | 0.0209 |
Rheumatoid factor-negative | 18 (48.6) | 32 (26.0) |
Relationship between HLA-DRB1 allele carrier status and anticitrullinated protein/peptide autoantibody status
Carrier status | Odds ratio (95% confidence interval) |
P
| P for trend | ||
---|---|---|---|---|---|
Yes | No | ||||
S1 carrier | |||||
CCP2-positive | 32 (57.1) | 78 (75.0) | 0.44 (0.21–0.94) | 0.0312 | 0.0134 |
CCP2-negative | 24 (42.9) | 26 (25.0) | |||
AhFibA-positive | 31 (55.4) | 77 (74.0) | 0.43 (0.21–0.91) | 0.0213 | 0.0113 |
AhFibA-negative | 25 (44.6) | 27 (26.0) | |||
CCP2-positive | |||||
CCP2-negative | 49 (83.1) | 61 (60.4) | 3.21 (1.39–7.9) | 0.0028* | 0.0049* |
AhFibA-positive | 10 (16.9) | 40 (39.6) | |||
AhFibA-negative | 50 (84.8) | 58 (57.4) | 4.12 (1.75–10.49) | 0.0004* | 0.0003* |
CCP2-positive | 9 (15.2) | 43 (42.6) | |||
S3P carrier | |||||
CCP2-positive | 61 (79.2) | 49 (59.0) | 2.65 (1.24–5.74) | 0.0066* | 0.0014* |
CCP2-negative | 16 (20.8) | 34 (41.0) | |||
AhFibA-positive | 61 (79.2) | 47 (56.6) | 2.92 (1.38–6.32) | 0.0025* | 0.0035* |
AhFibA-negative | 16 (20.8) | 36 (43.4) | |||
S3D carrier | |||||
CCP2-positive | 17 (45.9) | 93 (75.6) | 0.27 (0.12–0.63) | 0.0011* | 0.0009* |
CCP2-negative | 20 (54.1) | 30 (24.4) | |||
AhFibA-positive | 19 (51.4) | 89 (72.4) | 0.4 (0.18–0.93) | 0.0266 | 0.0145 |
AhFibA-negative | 18 (48.6) | 34 (27.6) |